Literature DB >> 20085856

Improved synthesis of a fluorogenic ceramidase substrate.

Zuping Xia1, Jeremiah M Draper, Charles D Smith.   

Abstract

Substantial interest has focused on the roles of sphingolipid metabolizing enzymes in a variety of hyperproliferative and inflammatory diseases. A key family of enzymes involved in these pathologies is the ceramidases. Ceramidases cleave the pro-apoptotic lipid ceramide into a long-chain fatty acid and sphingosine, which can then be further metabolized to the mitogenic and inflammatory lipid sphingosine 1-phosphate. Consequently, development of ceramidase inhibitors would provide useful pharmacologic probes for further studies of sphingolipid metabolism, as well as lead compounds for drug development. This effort has been hampered by the lack of in vitro and cellular ceramidase assays that are amenable to high-throughput screening. Recently, a fluorogenic ceramide analog has been described as a substrate for use in ceramidase assays. The synthesis of this compound has now been substantially improved in terms of both the required effort and the overall yield of the process. Key improvements include: reduction in number of required steps, use of a hydroboration reaction; incorporation of a Mitsunobu reaction; improved acylation by the addition of triethylamine; together providing a fourfold increase in the overall yield. In addition, it has been demonstrated that the ceramide analog can be used in high-throughput assays to identify ceramidase inhibitors. Overall, the improved efficiency in the preparation of this ceramidase substrate should accelerate discovery efforts relating to sphingolipid metabolism. Copyright (c) 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20085856      PMCID: PMC2841511          DOI: 10.1016/j.bmc.2009.12.071

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  Antitumor activity of sphingosine kinase inhibitors.

Authors:  Kevin J French; John J Upson; Staci N Keller; Yan Zhuang; Jong K Yun; Charles D Smith
Journal:  J Pharmacol Exp Ther       Date:  2006-04-21       Impact factor: 4.030

Review 2.  Medicinal chemistry aspects of drug targets in sphingolipid metabolism.

Authors:  Peter Nussbaumer
Journal:  ChemMedChem       Date:  2008-04       Impact factor: 3.466

3.  Human acid ceramidase is overexpressed but not mutated in prostate cancer.

Authors:  R S Seelan; C Qian; A Yokomizo; D G Bostwick; D I Smith; W Liu
Journal:  Genes Chromosomes Cancer       Date:  2000-10       Impact factor: 5.006

Review 4.  Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report.

Authors:  J S Norris; A Bielawska; T Day; A El-Zawahri; S ElOjeimy; Y Hannun; D Holman; M Hyer; C Landon; S Lowe; J Y Dong; J McKillop; K Norris; L Obeid; S Rubinchik; M Tavassoli; S Tomlinson; C Voelkel-Johnson; X Liu
Journal:  Cancer Gene Ther       Date:  2006-06-09       Impact factor: 5.987

Review 5.  Principles of bioactive lipid signalling: lessons from sphingolipids.

Authors:  Yusuf A Hannun; Lina M Obeid
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

Review 6.  Lipid signalling in disease.

Authors:  Matthias P Wymann; Roger Schneiter
Journal:  Nat Rev Mol Cell Biol       Date:  2008-02       Impact factor: 94.444

Review 7.  Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy.

Authors:  Andrea Huwiler; Uwe Zangemeister-Wittke
Journal:  Crit Rev Oncol Hematol       Date:  2007-06-07       Impact factor: 6.312

8.  Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells.

Authors:  David H Holman; Lorianne S Turner; Ahmed El-Zawahry; Saeed Elojeimy; Xiang Liu; Jacek Bielawski; Zdzislaw M Szulc; Kristi Norris; Youssef H Zeidan; Yusuf A Hannun; Alicja Bielawska; James S Norris
Journal:  Cancer Chemother Pharmacol       Date:  2007-04-12       Impact factor: 3.333

9.  Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy.

Authors:  Saeed Elojeimy; Xiang Liu; John C McKillop; Ahmed M El-Zawahry; David H Holman; Jonathan Y Cheng; William D Meacham; Ayman Em Mahdy; Antonio F Saad; Lorianne S Turner; Joseph Cheng; Terrence A Day; Jian-Yun Dong; Alicja Bielawska; Yusuf A Hannun; James Scott Norris
Journal:  Mol Ther       Date:  2007-04-10       Impact factor: 11.454

10.  Total synthesis of (-)-balanol, all stereoisomers, their N-tosyl analogues, and fully protected ophiocordin: an easy route to hexahydroazepine cores from garner aldehydes.

Authors:  Ajay Kumar Srivastava; Gautam Panda
Journal:  Chemistry       Date:  2008       Impact factor: 5.236

View more
  3 in total

1.  Discovery and evaluation of inhibitors of human ceramidase.

Authors:  Jeremiah M Draper; Zuping Xia; Ryan A Smith; Yan Zhuang; Wenxue Wang; Charles D Smith
Journal:  Mol Cancer Ther       Date:  2011-09-01       Impact factor: 6.261

Review 2.  The emergence of acid ceramidase as a therapeutic target for acute myeloid leukemia.

Authors:  Su-Fern Tan; Jennifer M Pearson; David J Feith; Thomas P Loughran
Journal:  Expert Opin Ther Targets       Date:  2017-05-02       Impact factor: 6.902

3.  Fragment-Based Hologram QSAR Studies on a Series of 2,4-Dioxopyrimidine-1-Carboxamides As Highly Potent Inhibitors of Acid Ceramidase.

Authors:  Xiang-Lin Yang; Yuan Zhou; Xin-Ling Liu
Journal:  Iran J Pharm Res       Date:  2016       Impact factor: 1.696

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.